Tamtam Try Tamtam free
GSK logo

GSK account plan

Science-led global healthcare

At a glance

GSK is a biopharma group selling specialty medicines, vaccines and general medicines, with 2025 turnover of £32.7bn and 66,800 people.

GSK describes itself as a focused biopharma company that discovers, develops and delivers specialty medicines, vaccines and general medicines, with R&D centred on respiratory, immunology and inflammation, oncology, HIV (through ViiV Healthcare) and infectious diseases. It employs 66,800 people across 70 countries and runs 33 manufacturing sites. 2025 turnover was £32.7bn (+7% CER) and Core operating profit £9.8bn (+11% CER, margin 29.9%), with Core EPS of 172.0p and free cash flow of £4.0bn. The US is its largest region at £16.9bn of 2025 sales.

Business units

Strategic priorities

More than £40bn of sales by 2031
GSK targets sales above £40bn by 2031, with 15 launch opportunities each with peak sales potential above £2bn, and Specialty Medicines above 50% of sales.
Maximising launches
The CEO's 2026 focus starts with launch products such as Exdensur (twice-yearly severe asthma treatment) and Blenrep (multiple myeloma).
Accelerating the late-stage pipeline
A review accelerated 7 late-stage products across 18 indications, and GSK now expects 20+ phase III starts in 2026 (previously 10), including oncology ADCs, efimosfermin in MASH and long-acting TSLP.
Longer-acting HIV medicines
ViiV targets three-times-yearly Apretude for PrEP in H1 2027, three-times-yearly Cabenuva in 2028 and twice-yearly treatment by the end of the decade, to navigate the dolutegravir loss of exclusivity.
Targeted business development
Deals with a clear pathway to value creation: RAPT Therapeutics, 35Pharma and Nuvalent in 2026, after 14 partnerships and acquisitions in 2025.
Technology and AI at scale
The Chair asks the new CEO to adopt technology at scale; technology and AI are one of three R&D priorities and a source of savings in the Accelerate Growth programme.

Latest results

In Q2 2026, sales were £8,409m (+5% CER) and H1 sales £16,038m (+5% CER). Core operating profit rose 7% to £2,800m with a 33.3% margin, and Core EPS rose 9% to 50.5p. Specialty Medicines grew 14% to £3,782m and Vaccines 8%, while General Medicines fell 9%. Total operating profit fell 75% to £481m on a £1,334m camlipixant impairment and £371m on Alector-related assets. Guidance for 2026 at CER was reaffirmed: turnover +3% to 5% and Core operating profit +7% to 9%, both in the upper half, and Core EPS +7% to 9% in the lower half.

Investments and deals

Nuvalent acquisition
Closed 15 July 2026 for an equity value of about $10.6bn, funded mainly by debt, adding zidesamtinib and neladalkib in lung cancer.
RAPT Therapeutics and 35Pharma
RAPT (US$2.3bn, completed 3 March 2026) adds ozureprubart for food allergy; 35Pharma (US$1.0bn, completed 14 April 2026) adds HS235 for pulmonary hypertension.
Accelerate Growth programme
Targets £1.9bn of annual savings by 2029 for £2.4bn of costs, through technology and AI, support services, procurement and a simpler supply chain and site network; savings are mainly reinvested in R&D and business development.
Manufacturing and R&D sites
$1.2bn over five years in US advanced manufacturing, AI and digital, including a biologics flex factory at Upper Merion, Pennsylvania; a new flagship R&D centre is planned on the Cambridge Biomedical Campus, UK.

Challenges and risks

US pricing and policy
US policy on international reference pricing, tariffs and the IRA Medicare Part D redesign weigh on sales; the April 2026 agreement gives Section 232 tariff relief through 20 January 2029.
Dolutegravir loss of exclusivity
Dolutegravir loses exclusivity during 2028-2030, starting April 2028 in the US, with most of the impact in 2029-2030.
Weaker US vaccine demand
US demand for Shingrix and Arexvy declined in 2025, with Shingrix US sales down 17%, amid vaccine hesitancy and competition.
Pipeline setbacks
The CALM-1 and CALM-2 trials of camlipixant showed limited efficacy, leading to a £1,334m impairment in Q2 2026.
Cyber and supply continuity
The annual report rates information and cyber security and supply continuity among principal risks increasing externally.

What leadership says

“Accelerating R&D is our biggest opportunity to create value as a company.”

Luke Miels, Chief Executive Officer · GSK Annual Report 2025, March 2026

“Products are the key in this business, and we need to be more product-centric.”

Luke Miels, Chief Executive Officer · FY and Q4 2025 results call, 4 February 2026

“We remain focused on operational delivery, execution, and accelerating R&D.”

Luke Miels, Chief Executive Officer · Q2 2026 results announcement, 28 July 2026

“has underperformed for many years and this marks only the start of a long-awaited recovery.”

Sir Jonathan Symonds, Chair · Chair's statement on the share price, GSK Annual Report 2025

Where a supplier can help

Clinical trial capacity
Tied to the pipeline acceleration: going from 10 to 20+ phase III starts in 2026 creates demand for CROs, site networks and trial technology.
Launch commercialisation support
Tied to the Exdensur and Blenrep launches: patient access, field-force and HCP engagement services for launches GSK calls its first focus area.
AI, procurement and support-service efficiency
Tied to the Accelerate Growth programme: savings are to come from technology and AI, streamlining support services and procurement.
Manufacturing and site network
Tied to the US manufacturing investment and supply-chain simplification: equipment, automation and digital tools for new and consolidated sites.
Integration of acquired biotechs
Tied to the Nuvalent, RAPT and 35Pharma acquisitions: systems, data and regulatory integration of newly acquired programmes.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like GSK?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about GSK

What does GSK do?

GSK discovers, develops and sells specialty medicines, vaccines and general medicines, focusing on respiratory, immunology and inflammation, oncology, HIV and infectious diseases.

What is GSK's revenue?

2025 turnover was £32.7bn (+7% CER) with Core operating profit of £9.8bn. H1 2026 sales were £16,038m (+5% CER).

How many employees does GSK have?

GSK has 66,800 people across 70 countries and 33 manufacturing sites, according to its 2025 Annual Report.

Who leads GSK?

Luke Miels succeeded Emma Walmsley as CEO at the end of 2025. Sir Jonathan Symonds is Chair and Julie Brown is CFO.

What is GSK's strategy?

GSK aims for sales above £40bn by 2031 by maximising launches, accelerating its late-stage pipeline, extending long-acting HIV medicines and adding assets through targeted business development.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)